Table 1 Screened infants requiring treatment, primary and secondary treatment modalities, and outcomes
From: Analysis of a two-year independent screening effort for retinopathy of prematurity in rural Egypt
Total Requiring Treatment | 63 | |
Refused or Lost Follow Up | 15 (23.8%) | |
Deatha | 1 (1.6%) | |
Received Treatment | 47 (74.6%) | |
OD | OS | |
Primary Treatment | 44 | 40 |
Intravitreal Ranibizumab | 38 (83.4%) | 35 (87.5%) |
Laser Ablation | 4 (9.1%) | 4 (10%) |
Surgery | 2 (4.5%) | 1 (2.5%) |
Recurrence | 7 (15.9%) | 7 (17.5%) |
Secondary Treatment | ||
Intravitreal Ranibizumab | 5 (11.4%) | 4 (10%) |
Laser Ablation | 3 (6.8%) | 3 (7.5%) |
Surgery | 0 (0) | 1 (2.5%) |
Final Outcome | ||
Full Vascularization | 40 (90.9%) | 35 (87.5%) |
Arrested Vascularity | 4 (9.1%) | 4 (10%) |
Progression of ROP | 0 (0%) | 1 (2.5%) |